Cargando…
PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine
PURPOSE: [(11)C]methionine ([(11)C]Met) was used for cancer imaging based on upregulated amino acid transport and protein synthesis in different tumor types. However, the short half-life of (11)C decay limited further clinical development of [(11)C]Met. Synthetic amino acid analog anti-1-amino-3-[(1...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531569/ https://www.ncbi.nlm.nih.gov/pubmed/31119488 http://dx.doi.org/10.1186/s13550-019-0519-4 |
_version_ | 1783420859847802880 |
---|---|
author | Sergeeva, Olga Zhang, Yifan Kenyon, Jonathan D. Miller-Atkins, Galen A. Wu, Chunying Iyer, Renuka Sexton, Sandra Wojtylak, Patrick Awadallah, Amad Xin, Wei Chan, E. Ricky O’Donnel, James K. Lee, Zhenghong |
author_facet | Sergeeva, Olga Zhang, Yifan Kenyon, Jonathan D. Miller-Atkins, Galen A. Wu, Chunying Iyer, Renuka Sexton, Sandra Wojtylak, Patrick Awadallah, Amad Xin, Wei Chan, E. Ricky O’Donnel, James K. Lee, Zhenghong |
author_sort | Sergeeva, Olga |
collection | PubMed |
description | PURPOSE: [(11)C]methionine ([(11)C]Met) was used for cancer imaging based on upregulated amino acid transport and protein synthesis in different tumor types. However, the short half-life of (11)C decay limited further clinical development of [(11)C]Met. Synthetic amino acid analog anti-1-amino-3-[(18)F]fluoro-cyclobutyl-1-carboxylic acid ([(18)F]FCABC) was developed and FDA-approved for PET imaging of recurrent prostate cancer. This study investigated “repurposed” [(18)F]FACBC for PET imaging of primary liver cancer such as hepatocellular carcinoma (HCC) in comparison with [(11)C]Met. METHODS: [(11)C]Met was synthesized in the lab, and [(18)F]FACBC was purchased from a commercial outlet. A clinically relevant animal model of spontaneously developed HCC in the woodchucks was used for PET imaging. Bioinformatics analysis was performed for the expression of amino acid transporters responsible for radiotracer uptake and validated by PCR. Dynamic PET scans of [(11)C]Met and [(18)F]FACBC were acquired within 1 week. Standardized uptake value (SUV) was calculated for regions of interest (ROIs) defined over HCC and a liver background region. H&E staining and immunohistochemical (IHC) staining were performed with harvested tissues post-imaging. RESULTS: Higher expression of ACST2 and LAT1 was found in HCC than in the surrounding liver tissues. PCR validated this differential expression. [(11)C]Met and [(18)F]FACBC displayed some differences in their uptake and retention in HCC. Both peaked in HCC with an SUV of 3.5 after 10 min post-injection. Met maintained a plateaued contrast uptake in HCC to that in the liver while [(18)F]FCABC declined in HCC and liver after peak uptake. The pathological assessment revealed the liver tumor as moderately differentiated similar to the human HCC and proliferative. CONCLUSION: Both [(18)F]FACBC and [(11)C]Met showed uptake in HCC through the use of a clinically relevant animal model of woodchuck HCC. The uptake and retention of [(18)F]FACBC and [(11)C]Met depend on their metabolism and also rely on the distribution of their principal amino acid transporters. |
format | Online Article Text |
id | pubmed-6531569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-65315692019-06-07 PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine Sergeeva, Olga Zhang, Yifan Kenyon, Jonathan D. Miller-Atkins, Galen A. Wu, Chunying Iyer, Renuka Sexton, Sandra Wojtylak, Patrick Awadallah, Amad Xin, Wei Chan, E. Ricky O’Donnel, James K. Lee, Zhenghong EJNMMI Res Original Research PURPOSE: [(11)C]methionine ([(11)C]Met) was used for cancer imaging based on upregulated amino acid transport and protein synthesis in different tumor types. However, the short half-life of (11)C decay limited further clinical development of [(11)C]Met. Synthetic amino acid analog anti-1-amino-3-[(18)F]fluoro-cyclobutyl-1-carboxylic acid ([(18)F]FCABC) was developed and FDA-approved for PET imaging of recurrent prostate cancer. This study investigated “repurposed” [(18)F]FACBC for PET imaging of primary liver cancer such as hepatocellular carcinoma (HCC) in comparison with [(11)C]Met. METHODS: [(11)C]Met was synthesized in the lab, and [(18)F]FACBC was purchased from a commercial outlet. A clinically relevant animal model of spontaneously developed HCC in the woodchucks was used for PET imaging. Bioinformatics analysis was performed for the expression of amino acid transporters responsible for radiotracer uptake and validated by PCR. Dynamic PET scans of [(11)C]Met and [(18)F]FACBC were acquired within 1 week. Standardized uptake value (SUV) was calculated for regions of interest (ROIs) defined over HCC and a liver background region. H&E staining and immunohistochemical (IHC) staining were performed with harvested tissues post-imaging. RESULTS: Higher expression of ACST2 and LAT1 was found in HCC than in the surrounding liver tissues. PCR validated this differential expression. [(11)C]Met and [(18)F]FACBC displayed some differences in their uptake and retention in HCC. Both peaked in HCC with an SUV of 3.5 after 10 min post-injection. Met maintained a plateaued contrast uptake in HCC to that in the liver while [(18)F]FCABC declined in HCC and liver after peak uptake. The pathological assessment revealed the liver tumor as moderately differentiated similar to the human HCC and proliferative. CONCLUSION: Both [(18)F]FACBC and [(11)C]Met showed uptake in HCC through the use of a clinically relevant animal model of woodchuck HCC. The uptake and retention of [(18)F]FACBC and [(11)C]Met depend on their metabolism and also rely on the distribution of their principal amino acid transporters. Springer Berlin Heidelberg 2019-05-22 /pmc/articles/PMC6531569/ /pubmed/31119488 http://dx.doi.org/10.1186/s13550-019-0519-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Sergeeva, Olga Zhang, Yifan Kenyon, Jonathan D. Miller-Atkins, Galen A. Wu, Chunying Iyer, Renuka Sexton, Sandra Wojtylak, Patrick Awadallah, Amad Xin, Wei Chan, E. Ricky O’Donnel, James K. Lee, Zhenghong PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine |
title | PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine |
title_full | PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine |
title_fullStr | PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine |
title_full_unstemmed | PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine |
title_short | PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with l-[S-methyl-(11)C]methionine |
title_sort | pet imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)f]fluorocyclobutanecarboxylic acid in comparison with l-[s-methyl-(11)c]methionine |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531569/ https://www.ncbi.nlm.nih.gov/pubmed/31119488 http://dx.doi.org/10.1186/s13550-019-0519-4 |
work_keys_str_mv | AT sergeevaolga petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT zhangyifan petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT kenyonjonathand petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT milleratkinsgalena petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT wuchunying petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT iyerrenuka petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT sextonsandra petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT wojtylakpatrick petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT awadallahamad petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT xinwei petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT chanericky petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT odonneljamesk petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine AT leezhenghong petimagingofhepatocellularcarcinomawithanti1amino318ffluorocyclobutanecarboxylicacidincomparisonwithlsmethyl11cmethionine |